trovafloxacin

01/01/1999 - "Trovafloxacin has shown to be effective in the treatment of infections due to Chlamydia with excellent clinical results and a good tolerance. "
08/01/1999 - "In doses ranging from 200 mg to 50 mg daily for a week and 200 mg daily for 5 days, trovafloxacin appears to be effective for chlamydial infections and is well tolerated."
07/01/1999 - "These data show that trovafloxacin might be effective in intraabdominal infections caused by mixed aerobic and anaerobic microorganisms."
12/01/1998 - "These results indicate that trovafloxacin may be effective in prophylaxis and treatment of mixed infections in surgical patients."
08/01/1998 - "These PET results suggest that trovafloxacin will be useful in the treatment of a broad range of infections at diverse anatomic sites."

09/01/2000 - "Trovafloxacin is the first fluoroquinolone effective in preventing experimental streptococcal endocarditis."
01/01/1999 - "The efficacy of trovafloxacin against Staphylococcus aureus and viridans group streptococci was investigated in vitro and in an experimental model of endocarditis. "
01/01/1999 - "Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis."
09/01/2000 - "Successful trovafloxacin prophylaxis against experimental streptococcal aortic valve endocarditis."
09/01/2000 - "Trovafloxacin treatment of viridans group Streptococcus experimental endocarditis."

01/01/2001 - "coli, trovafloxacin could be beneficial in the treatment of intra-abdominal abscesses."
03/01/1997 - "In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli."
12/01/1998 - "Drug concentrations were greater in intra-abdominal abscesses than in serum, reflecting the good tissue penetration of trovafloxacin. "
12/01/1998 - "In these experimental models, trovafloxacin protected rats from lethal infection, reduced intra-abdominal abscess formation, and inhibited bacterial growth. "
09/01/1997 - "We investigated the efficacy of trovafloxacin, a new quinolone, in comparison with that of clindamycin in the treatment of intra-abdominal abscesses caused by Bacteroides fragilis in young and senescent mice. "

01/01/2000 - "The penetration of trovafloxacin (TVA), 200 mg once daily, into the airways of 17 patients with severe pneumonia was studied. "
01/01/2000 - "Trovafloxacin concentrations in airway fluids of patients with severe community-acquired pneumonia."
06/01/1999 - "Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia."
01/01/1999 - "In this sense special reference is made to trovafloxacin, listing its principal characteristics, as its broad spectrum of activity, its excellent pharmacokinetic properties, its availability in i.v. and oral formulations and its good tolerance, which makes trovafloxacin a very interesting option for treatment of hospital acquired pneumonia."
01/01/1999 - "[The role of trovafloxacin in the treatment of nosocomial pneumonia]."

05/01/2001 - "The pharmacodynamic and pharmacokinetic properties of trovafloxacin were studied in a standardized murine model of established subcutaneous abscesses. "
09/01/1997 - "Trovafloxacin therapy sterilized abscesses in 94% of young mice and in 73% of old mice, but this difference was not significant. "
03/01/1997 - "The measured peak levels of trovafloxacin in serum and abscess pus were 2.6 +/- 0.3 and 5.2 micrograms/ml, respectively. "
09/01/2005 - "coli 7.4 log CFU/abscess) on day 8. Also, moxifloxacin was more potent than trovafloxacin. "
09/01/2005 - "coli to 4.9 +/- 0.09 and 4.2 +/- 0.07 log CFU/abscess for trovafloxacin and moxifloxacin, respectively, compared to controls (B. "